Table 3.

Comparison of clinical outcomes in those patients who had gut dominated by bifidobacterium versus bacteroides genera using mixed effect models correcting for age, gender, sputum organisms (except for FEV¹) and clustering by patient

Clinical outcomes	Dominant genus				Bifidobacterium versus Bacteroides (95% CI)	P
	Bifidobacterium		Bacteroides
	N	Adjusted estimate ± sd	N	Adjusted estimate ± sd
Pulmonary exacerbations (N)	19	1.6 ± 1.5	13	2.9 ± 1.6	IRR = 0.55 (0.25 to 0.82)	0.01
FEV1 (percentage of predicted value)	22	103.48 ± 1.39	15	83.97 ± 1.48	Coef = 20.00 (8.05 to 31.92)	0.001
Calprotectin (µg/g of feces)	19	80.05 ± 61.43	13	107.73 ± 37.97	Coef =  − 16.53 (− 26.80 to − 6.26)	0.002
Days of prescribed antibiotics in past 6-months (N)	19	25.8 ± 6.8	13	60.3 ± 5.9	IRR = 0.43 (0.22 to 0.69)	0.04

Data includes dominant genus and clinical outcomes reported at baseline and 12-month visits